ArticlebioRxiv : the preprint server for biology2025
Smelling the Risk: Early Olfactory Deficits, Brain Networks, and Blood Markers of Alzheimer's Disease Risk in Humanized APOE Mice.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Olfactory impairment is a hallmark of early Alzheimer's disease (AD), but the underlying mechanisms connecting sensory decline to genetic and environmental risk factors remain unclear. Our integrative analysis combines ethologically relevant olfactory behavior assays, high-resolution diffusion MRI connectomics, and blood transcriptomics in a large cohort of humanized APOE mice stratified by APOE genotype (APOE2, APOE3, APOE4), age, sex, high-fat diet, and immune background (HN). Behaviorally, APOE4 mice exhibited accelerated deficits in odor salience, novelty detection, and memory, especially when exposed to a high-fat diet, whereas APOE2 mice showed resilience (ANOVA: APOE x HN, F(2,1669)=77.25, p<0.001, eta squared effect size = 0.08). Notably, age and diet exerted compounding effects, with older and HFD-fed mice displaying reduced odor-guided exploration (diet x age: F(1,1669)=16.04, p<0.001, eta squared effect size = 0.01). Memory analyses revealed robust genotype- and age-dependent impairments: at 24- and 48-hour delays, recognition indices were significantly lower in APOE4 mice compared to APOE2 (long-term memory: APOE x HN, F(2,395)=5.6, p=0.004). Elastic Net-regularized multi-set canonical correlation analysis (MCCA) linked behavior to brain network substrates, revealing subnetworks whose connectivity explained up to 24 percent of behavioral variance (sum of canonical correlations: 1.27, 95% CI [1.18, 1.85], p<0.0001). High-weighted connections between the ventral orbital cortex, somatosensory cortex, and cerebellar-brainstem pathways were identified as critical nodes for risk or compensation. Integrative blood transcriptomics revealed eigengene modules strongly correlated with imaging changes in olfactory-memory circuits (for example, eigengene 2 vs. subiculum diffusivity: r = -0.5, p < 1e-30, explaining up to 24 percent of variance). Gene ontology analysis pinpointed shared pathways in synaptic signaling, translation, and metabolic regulation across brain and blood. Notably, glutamatergic and synaptic pathways were enriched among genes linking peripheral and central compartments. Collectively, these results demonstrate that olfactory behavior, quantitatively shaped by genotype, age, diet, and immune status, serves as a sensitive and translatable early biomarker of Alzheimer's disease risk. Our systems-level approach identifies specific brain networks and peripheral molecular signatures underlying sensory-cognitive vulnerability, providing a robust framework for early detection and targeted intervention in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.